4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
暂无分享,去创建一个
Inkyung Jung | Sang Wun Kim | Sunghoon Kim | E. Shin | Su‐Hyung Park | Junsik Park | Seongyeol Park | B. Choi | S. Choi | Minwoo Jeon | Y. Lee | Jung Yun Lee | Galam Leem | Y. Ju | Eui-Soon Kim
[1] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[2] L. Landi,et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer , 2019, Journal of Immunotherapy for Cancer.
[3] Hualiang Jiang,et al. Selective activation of TWIK-related acid-sensitive K+ 3 subunit–containing channels is analgesic in rodent models , 2019, Science Translational Medicine.
[4] S. Berger,et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.
[5] J. Werner,et al. Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer , 2019, Cancers.
[6] Y. Chung,et al. Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer. , 2019, Pathology, research and practice.
[7] D. Welch,et al. Defining the Hallmarks of Metastasis. , 2019, Cancer research.
[8] C. Klein,et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy , 2019, Science Translational Medicine.
[9] L. Strigari,et al. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab , 2019, Journal of Translational Medicine.
[10] M. Good,et al. Challenges and strategies for developing efficacious and long-lasting malaria vaccines , 2019, Science Translational Medicine.
[11] Hanzi Xu,et al. Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets , 2019, Journal of Ovarian Research.
[12] Daniel E. Speiser,et al. Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.
[13] T. Schumacher,et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers , 2018, Nature Medicine.
[14] J. Zapata,et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity , 2018, Nature Communications.
[15] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[16] S. Leschka,et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) , 2018, Cancer Immunology, Immunotherapy.
[17] B. Fox,et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.
[18] A. Hoos,et al. The promise and challenges of immune agonist antibody development in cancer , 2018, Nature Reviews Drug Discovery.
[19] C. Klein,et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.
[20] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[21] D. Provencher,et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. , 2018 .
[22] Young Tae Kim,et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy , 2018, BMC Cancer.
[23] Jian Yu,et al. Immunogenic effects of chemotherapy-induced tumor cell death , 2018, Genes & diseases.
[24] D. Bedognetti,et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..
[25] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[26] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[27] Hidekazu Suzuki,et al. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial , 2018, PloS one.
[28] I. Melero,et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.
[29] Harini Veeraraghavan,et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.
[30] M. Milano,et al. Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. , 2017, Journal of thoracic disease.
[31] C. Morrison,et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. , 2017, Gynecologic oncology.
[32] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[33] S. Rosenberg,et al. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression , 2016, Clinical Cancer Research.
[34] H. Clevers,et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells , 2016, Nature Immunology.
[35] R. Levy,et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.
[36] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[37] Yulei N. Wang,et al. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) , 2016 .
[38] Aviv Regev,et al. A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells , 2016, Cell.
[39] H. Hollema,et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. , 2016, European journal of cancer.
[40] C. Ware,et al. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. , 2016, Immunity.
[41] H. Streeck,et al. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity , 2016, The Journal of Immunology.
[42] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[43] J. Weon,et al. The MAGE protein family and cancer. , 2015, Current opinion in cell biology.
[44] S. Rosenberg,et al. Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes , 2015, Journal of Immunotherapy for Cancer.
[45] K. Yamaguchi,et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Yiping Yang,et al. Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.
[47] Mark Peakman,et al. More tricks with tetramers: a practical guide to staining T cells with peptide–MHC multimers , 2015, Immunology.
[48] I. Melero,et al. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. , 2015, Seminars in oncology.
[49] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] B. Nelson. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. , 2015, Current opinion in immunology.
[51] E. Wherry,et al. Overcoming T cell exhaustion in infection and cancer. , 2015, Trends in immunology.
[52] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[53] Y. Song,et al. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing BMC Cancer Sample , 2015 .
[54] M. Merad,et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.
[55] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[56] L. Molinero,et al. T cell-NF-κB activation is required for tumor control in vivo , 2015, Journal of Immunotherapy for Cancer.
[57] P. Hwu,et al. Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy , 2014, Clinical Cancer Research.
[58] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[59] S. Rosenberg. Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment , 2014, Nature Reviews Clinical Oncology.
[60] Y. Nordby,et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure‐free survival in prostate cancer , 2014, The Prostate.
[61] K. Hemminki,et al. Metastatic sites and survival in lung cancer. , 2014, Lung cancer.
[62] C. Drake,et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer , 2014, Journal of Immunotherapy for Cancer.
[63] J. Galon,et al. Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014, Clinical Cancer Research.
[64] M. Berger,et al. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing , 2014, Molecular Oncology.
[65] G. Coukos,et al. CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.
[66] Ali Bashashati,et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.
[67] Lieping Chen,et al. Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.
[68] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[69] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[70] E John Wherry,et al. T cell exhaustion , 2011 .
[71] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[72] A. Sewell,et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers , 2009, Journal of immunological methods.
[73] Surojit Sarkar,et al. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates , 2008, The Journal of experimental medicine.
[74] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[75] Y. Benjamini,et al. Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.
[76] D. Speiser,et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion , 2015, The EMBO journal.
[77] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[78] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .